Education
About Us
Working with TipRanks
Follow Us
Tryptamine Therapeutics Limited (AU:TYP)
ASX:TYP
Total Valuation
Tryptamine Therapeutics has a market cap or net worth of AU$47.48M. The enterprise value is AU$18.55M.
Market CapAU$47.48M
Enterprise ValueAU$18.55M
Share Statistics
Tryptamine Therapeutics has 1,438,921,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,438,921,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Tryptamine Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count50
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Tryptamine Therapeutics is ―. Tryptamine Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Tryptamine Therapeutics had revenue of ― and earned -10.08M in profits. Earnings per share was ―.
Revenue―
Gross Profit99.73K
Operating Income-14.11M
Pretax Income―
Net Income-10.08M
EBITDA-8.27M
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Tryptamine Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.60
52-Week Price Change0.00%
50-Day Moving Average0.04
200-Day Moving Average0.03
Relative Strength Index (RSI)43.10
Average Volume (3m)1.23M
Important Dates
Tryptamine Therapeutics upcoming earnings date is Feb 20, 2025, TBA Not Confirmed.
Last Earnings DateSep 6, 2024
Next Earnings DateFeb 20, 2025
Ex-Dividend Date―
Financial Position
Tryptamine Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Tryptamine Therapeutics has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Tryptamine Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Tryptamine Therapeutics has ― in cash and marketable securities with 0.00 in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt0.00
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Tryptamine Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―